Diabetes drug improves cardiovascular outcomes across a range of heart and kidney conditions

According to Dr Brendon Neuen, a senior research fellow at The George Institute for Global Health, “Despite the various benefits of SGLT2 inhibitors on cardiovascular-kidney-metabolic diseases, this class of medicine remains under-prescribed." …